Remote Interpreting Services
As the world is adjusting to a new normal, companies are finding alternatives for face-to-face meetings and events.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
RWS Life Sciences offers translation, content management and intellectual property services for pharmaceutical and life sciences companies. We connect customers with people worldwide by communicating content at scale, to allow ideas and innovations to be protected and realised.
We provide localisation, translation and transcreation services, as well as translation management technology, machine translation and translation productivity tools, to help companies expand their reach globally.
Our solutions can help you make processes more efficient, lower translation costs, and expedite time to market. They can increase real value for your teams and ecosystem partners to improve outcomes for scientists, medical representatives, professionals, and patients.
Translations are essential for advancing clinical trials, and RWS’ understanding of and emphasis on the life sciences industry allows us to confidently handle all translation requests.
Our clinical trial management services begin by thoroughly analysing projects, allowing us to discern the most appropriate translation solution for each request and customise as necessary. We follow flexible procedures so we can deliver in the most timely and cost-effective manner.
Documents we can translate include protocols, protocol synopses, case report forms (CRFs), electronic clinical outcomes assessments (eCOAs), adverse event reports, electronic patient-reported outcomes (ePROs), patient records, and event logs.
RWS is a dependable partner for the linguistic validation and management of clinical outcomes assessments (COAs). Our translations are accurate and match the source instrument in conceptual and cultural terms, whether the assessment is for a patient, clinician or observer.
Our linguistic validation process is based on the US Food and Drug Administration’s (FDA) patient-reported outcome (PRO) guidance document, as well as the good practice recommendations set out by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
We partner with translators, interviewers, instrument developers, survey research experts, clinicians and in-country reviewers worldwide, allowing us to undertake each validation project with ease and scientific accuracy.
Patient safety depends on accurate pharmaceutical product information, so RWS prioritises translating product materials accurately. Our industry specialisation and knowledge of regulatory standards and terminology guarantee accurate and timely translation.
All our translations are translated by two highly qualified linguists and undergo multilingual multimedia production, a further quality control edit, a final pre-production review, and a domestic review before being certified.
Our translations follow methods stipulated by global healthcare regulatory bodies, including the European Medicines Agency (EMA).
We can translate a wide range of pharmaceutical product documents, including patient information leaflets (PILs), summaries of product characteristics (SmPCs), pharmaceutical product information, packaging inserts, patient prescription information, and regulatory correspondence.
RWS’s translation experts and linguists are committed to handling the unique requirements of medical and in-vitro device projects, including labelling, product manuals and patents.
Through our ISO 13485-certified translation processes, routine risk assessment procedures, technology solutions, and intelligent use of translation memory, we can provide clients with translations of the highest possible quality.
Among other documents, we can translate packaging inserts and labels, usage instructions, operating and installation manuals, manufacturing procedures, patents, data sheets, regulatory compliance documents, and software applications.
RWS has more than 60 years’ worth of translation experience and knowledge. We take clients’ content and ideas to worldwide audiences using our smart technology, deep expertise, and collective global intelligence.
We partner with pharmaceutical, medical, chemical, technology, financial services, legal, telecommunications and automotive companies, as well as governmental organisations, in Europe, Asia-Pacific, North America, and South America.
As the world is adjusting to a new normal, companies are finding alternatives for face-to-face meetings and events.
Around the world, companies across industries are producing massive volumes of content each day, and life sciences companies are no exception.
RWS' wide range of end-to-end technology-enabled localisation services allows you to connect with global audiences and deliver outstanding customer experiences in any market.
The work of pharmacovigilance teams is of critical importance in clinical development and in ensuring the long-term safety of pharmaceutical products.
RWS can support your global language needs by providing interpreting services for business meetings, conferences and events.
In any clinical trial, sponsors must ensure participants understand key information, including the trial’s possible risks and benefits.
In Safety & Pharmacovigilance, meeting very tight turnaround times while maintaining a high level of content quality and accuracy are key to successful reporting of adverse events to regulatory bodies and assessing safety-related information to determine benefit and risk impact.
Our client was able to save approximately a million euros per year by moving their Regulatory Affairs European Union Centralised Procedures (EU CP) submission work from being done internally through a managed service (technology + services) with RWS.
Usability Testing is a qualitative, patient-centred process designed to demonstrate that content validity has been maintained during format migration and to measure the usability of an eCOA platform by the target population.
RWS’s 2022 eBook, The Case for NMT in Life Sciences, walks you through the benefits of neural machine translation (NMT) as it pertains to life sciences.
A globally renowned patient recruitment company faced a significant increase in materials requiring translation to support multiple studies.
Do you want your trial participants to sift through complex and jargon-filled clinical trial summaries? Do you believe that every patient, healthcare professional, and caregiver deserves easy access to vital medical information?
One of the world’s largest pharmaceutical companies saves over ten million in translation spend through partnership and innovation with RWS Life Sciences.
Global content explosion needs deeper collaboration between humans and machines. AI is revolutionising how you can create, manage, translate and understand content.
When faced with unprecedented time constraints and high volume, innovative ideas and core partnerships are key. This is especially true for the Regulatory and Clinical portfolios, which require local language translation of more than 40,000 documents a year to enable successful authorisation.
Timeliness and quality of translations are key across a leading pharmaceutical corporation, however within the regulatory team of submissions management, it is an imperative requirement.
A life sciences company providing a full-line of clinical laboratory and end-to-end drug development services had a need to leverage RWS’s translation services.
A leading global pharmaceutical company asked RWS to deliver a machine translation (MT) solution that would deliver efficiency, scalability and return-on-investment for a patient safety/pharmacovigilance (PV) programme.
One of the world’s largest pharmaceutical companies saves more than 77 million in translation spend through partnership and innovation with RWS Life Sciences.
Industry’s first linguistic-AI solution wins ‘ Machine Translation Innovation Award’
Science-Based Targets initiative validates RWS’ commitment to reduce carbon emissions
RWS working with other industry leaders to bridge gap between AI innovation and policy
RWS, a company providing translation services for the pharmaceutical and life science industries, is among those exhibiting at DIA Europe 2024, the largest life sciences conference in Europe.
RWS, a company providing translation services for pharmaceutical and life sciences companies, is exhibiting at the CAHP conference in Palm Desert, California, this month. To be held from 23-25 October, the event will be the 37th edition of the annual conference.
Life sciences-focused translation company RWS will be giving two presentations at this year’s International Society for Quality-of-Life Research (ISOQOL) conference. The trade show will take place in Calgary, Alberta, from 18-21 October.
RWS, a leading provider of translation services for pharmaceutical and life sciences companies, will be exhibiting at the RAPS Convergence trade fair in Montreal from 3-5 October.
Pharmaceutical and life sciences translation company RWS will be giving a talk at the DIA 2023 conference, which will take place from 25-29 June in Boston, Massachusetts.
Pharmaceutical-focused translation company RWS will be exhibiting at the ISPOR conference taking place in Boston, Massachusetts, from 7-10 May.
For 35 years now, DIA EUROPE is the largest neutral event in the European life science industry – the knowledge hub between science, healthcare, and regulation – and the place to meet trusted colleagues and make new connections with the brightest minds passionate about advancing health priorities.
Key HEOR topics include medical technologies, clinical outcomes and real-world approaches in the healthcare sector.
RWS is excited to be exhibiting at #RAPS2022 in Phoenix, AZ, alongside many of the regulatory professionals working in the healthcare products industry.
RWS is attending DIA China 2022 in Suzhou, China! We are excited to be reconnecting with the life sciences community in person as well as having our very own Jeremy Wang presenting on COVID’s impact on Language Best Practices in Drug Development.
RWS is excited to be speaking and exhibiting at DIA 2022 in Chicago, Illinois, alongside many other life sciences companies working in lifecycle drug development and pharmacovigilance. We look forward to reconnecting with the life sciences community in person, as well as presenting in the Innovation Theatre: Advances through adversity: How Covid-driven innovation are becoming best practices for pharmacovigilance!
RWS Holdings, a recognised leader in structured and web content management technology, has acquired Liones Holding (Fonto) to fuel innovation and define the future of documents and content management
As the world's first genuine intelligence linguistic AI solution, RWS' Evolve allows pharmaceutical companies to harness the latest innovations in Generative AI in a fully secure, end-to-end Linguistic AI solution in a cost-efficient manner.